FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling. Compass Pathways executives discussed pricing as the COMP360 NDA nears completion, and state cannabis regulators say DEA still hasn’t answered their rescheduling questions.
The post Weekly Psychedelic Policy Briefing: October 12, 2026 appeared first on Psychedelics Today.
